Postconditioning with rosuvastatin reduces myocardial ischemia-reperfusion injury by inhibiting high mobility group box 1 protein expression

Experimental and Therapeutic Medicine

Volumn 7, Issue 1, 2013, Pages 117-120

  Du, Xianjin ^a   Hu, Xiaorong ^a,b   Wei, Jie ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUBEI POLYTECHNIC UNIVERSITY   (China)

Author keywords

High mobility group box 1 protein; Myocardial ischemia; Reperfusion; Rosuvastatin

Indexed keywords

CREATINE KINASE; HIGH MOBILITY GROUP B1 PROTEIN; LACTATE DEHYDROGENASE; MALONALDEHYDE; ROSUVASTATIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; IMMUNOBLOTTING; ISCHEMIC POSTCONDITIONING; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; STAINING;

EID: 84887963044     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1362     Document Type: Article

References (20)

1. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature418: 191-195, 2002.
2. Bell CW, Jiang W, Reich CF III and Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol291: C1318-C1325, 2006.
3. Andrassy M, Volz HC, Igwe JC, et al: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216-3226, 2008.
4. Hu X, Jiang H, Bai Q, et al: Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta406: 139-142, 2009.
5. Andrassy M, Volz HC, Riedle N, et al: HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med270: 245-253, 2011.
6. Hu X, Zhou W, Bai Q, et al: Increased serum high mobility group box 1 protein in patients with atrial fibrillation. Biomed Aging Pathol 1: 52-55, 2011.
7. Frangoginis NG, Smith CW and Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res53: 31-47, 2002.
8. Hu X, Fu W and Jiang H: HMGB1: a potential therapeutic target for myocardial ischemia and reperfusion injury. Int J Cardiol155: 489, 2012.
9. Jones SP, Gibson MF, Rimmer DM III, et al: Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol40: 1172-1178, 2002.
10. Nangle MR, Cotter MA and Cameron NE: Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes52: 2396-2402, 2003.
11. Susic D, Varagic J, Ahn J, et al: Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 42: 1091-1097, 2003.
12. Weinberg EO, Scherrer-Crosbie M, Picard MH, et al: Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Am J Physiol Heart Circ Physiol288: H1802-H1809, 2005.
13. Ke D, Fang J, Fan L, et al: Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury. Coron Artery Dis 24: 334-341, 2013.
14. Wang L, Zhang X, Liu L, et al: Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci Lett471: 152-156, 2010.
15. Jin D, Wu Y, Zhao L, et al: Atorvastatin inhibits serum HMGB1 level in patients with hyperlipidemia. Exp Ther Med4: 1124-1126, 2012.
16. Hu X, Zhou X, He B, et al: Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol638: 84-89, 2010.
17. McTaggart F, Buckett L, Davidson R, et al: Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol87: 28B-32B, 2001.
18. Bell RM and Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41: 508-515, 2003.
19. Tang D, Shi Y, Kang R, et al: Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 81: 741-747, 2007.
20. Tsung A, Klune JR, Zhang X, et al: HMGB1 release induced by liver ischemia involves Toll-like receptor 4 depedent reactive oxygen species production and calcium-mediated signaling. J Exp Med204: 2913-2923, 2007.